FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282922251> ?p ?o ?g. }

• W4282922251 endingPage "1890" @default.
• W4282922251 startingPage "1890" @default.
• W4282922251 abstract "Abstract Many ovarian cancer (OC) patients receiving chemotherapy relapse with acquired resistance, hence novel treatment allocation strategies are urgently needed. 3D cell culture models and organoid technologies have emerged as exciting tools to study cancer. Despite the advances, there is a need for protocols that can quickly generate patient-relevant 3D models for high-throughput drug screening and for diagnostic drug sensitivity testing. Ideally, such methods should be cost-effective, provide multi-parametric data to reveal distinct phenotypes, have single cell resolution to reveal heterogeneity and cell interactions, meet diagnostic timeframes and be miniaturized to allow the analysis of many drugs and combinations with small numbers of primary tumor cells. Here, we aimed to develop a robust technology for high-throughput ex vivo drug sensitivity testing for functional precision medicine using OC tissue and ascites samples (mostly high-grade serous carcinoma) from patients. We present a scalable drug screening platform: DETECT (Drug Efficacy Testing in Ex-vivo 3D Cultures), where tumor-derived patient cells can be rapidly screened within one week from sampling. Using this information patient-specific drug combinations are subsequently designed and tested with these data available within 9 days. This is much faster than with most screening protocols for organoids and PDC models where many weeks or months are required for establishment of the models and expansion of the required numbers of cells. We have currently tested the efficacy of 58 selected chemo- and targeted drugs in 5 doses using high content imaging and then a complete dose-matrix of 3 combinations at step 2. We report robust drug screening data in 15 out of 18 OC patient samples, which has resulted in a functional taxonomy of patient samples and a taxonomy of drugs based on their efficacy across patient samples. Some of the most common responses were seen for the BCL-XL inhibitor A-1331852 (9/15 patients), Topotecan (7), Dactinomycin (7), Omipalisib (6) and Omacetaxine (6). All but 2 drugs showed efficacy in at least one OC sample, suggesting heterogeneity and opportunities to make use of unique drug response patterns. Combination screening revealed that Carboplatin and A-1331852, a BCL-XL inhibitor, showed increased efficacy in 3 of the 5 tested patient samples. In conclusion, our 3D HT-drug testing assay DETECT with a combination screening capability could in the future be useful for guiding individualized treatment in a clinical setting as well as for identifying existing and emerging drugs and drug combinations for repurposing in OC. Citation Format: Emma Åkerlund, Greta Gudoityte, Elisabeth Moussaud Lamodiere, Joseph Carlson, Emelie Wallin, Josefin Fernebro, Olli Kallioniemi, Päivi Östling, Ulrika Joneborg, Brinton Seashore-Ludlow. Development of the drug efficacy testing in ex vivo 3D cultures (DETECT) platform and its application to functional precision medicine in ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1890." @default.
• W4282922251 created "2022-06-16" @default.
• W4282922251 creator A5003052965 @default.
• W4282922251 creator A5022018650 @default.
• W4282922251 creator A5046514159 @default.
• W4282922251 creator A5051159339 @default.
• W4282922251 creator A5052344842 @default.
• W4282922251 creator A5073093277 @default.
• W4282922251 creator A5073812413 @default.
• W4282922251 creator A5081518598 @default.
• W4282922251 creator A5088858308 @default.
• W4282922251 creator A5090796895 @default.
• W4282922251 date "2022-06-15" @default.
• W4282922251 modified "2023-10-07" @default.
• W4282922251 title "Abstract 1890: Development of the drug efficacy testing in <i>ex vivo</i> 3D cultures (DETECT) platform and its application to functional precision medicine in ovarian cancer" @default.
• W4282922251 doi "https://doi.org/10.1158/1538-7445.am2022-1890" @default.
• W4282922251 hasPublicationYear "2022" @default.
• W4282922251 type Work @default.
• W4282922251 citedByCount "0" @default.
• W4282922251 crossrefType "journal-article" @default.
• W4282922251 hasAuthorship W4282922251A5003052965 @default.
• W4282922251 hasAuthorship W4282922251A5022018650 @default.
• W4282922251 hasAuthorship W4282922251A5046514159 @default.
• W4282922251 hasAuthorship W4282922251A5051159339 @default.
• W4282922251 hasAuthorship W4282922251A5052344842 @default.
• W4282922251 hasAuthorship W4282922251A5073093277 @default.
• W4282922251 hasAuthorship W4282922251A5073812413 @default.
• W4282922251 hasAuthorship W4282922251A5081518598 @default.
• W4282922251 hasAuthorship W4282922251A5088858308 @default.
• W4282922251 hasAuthorship W4282922251A5090796895 @default.
• W4282922251 hasConcept C121608353 @default.
• W4282922251 hasConcept C126322002 @default.
• W4282922251 hasConcept C142724271 @default.
• W4282922251 hasConcept C143998085 @default.
• W4282922251 hasConcept C150903083 @default.
• W4282922251 hasConcept C163763905 @default.
• W4282922251 hasConcept C207001950 @default.
• W4282922251 hasConcept C26291073 @default.
• W4282922251 hasConcept C2780035454 @default.
• W4282922251 hasConcept C2780427987 @default.
• W4282922251 hasConcept C64903051 @default.
• W4282922251 hasConcept C71924100 @default.
• W4282922251 hasConcept C86803240 @default.
• W4282922251 hasConcept C98274493 @default.
• W4282922251 hasConceptScore W4282922251C121608353 @default.
• W4282922251 hasConceptScore W4282922251C126322002 @default.
• W4282922251 hasConceptScore W4282922251C142724271 @default.
• W4282922251 hasConceptScore W4282922251C143998085 @default.
• W4282922251 hasConceptScore W4282922251C150903083 @default.
• W4282922251 hasConceptScore W4282922251C163763905 @default.
• W4282922251 hasConceptScore W4282922251C207001950 @default.
• W4282922251 hasConceptScore W4282922251C26291073 @default.
• W4282922251 hasConceptScore W4282922251C2780035454 @default.
• W4282922251 hasConceptScore W4282922251C2780427987 @default.
• W4282922251 hasConceptScore W4282922251C64903051 @default.
• W4282922251 hasConceptScore W4282922251C71924100 @default.
• W4282922251 hasConceptScore W4282922251C86803240 @default.
• W4282922251 hasConceptScore W4282922251C98274493 @default.
• W4282922251 hasIssue "12_Supplement" @default.
• W4282922251 hasLocation W42829222511 @default.
• W4282922251 hasOpenAccess W4282922251 @default.
• W4282922251 hasPrimaryLocation W42829222511 @default.
• W4282922251 hasRelatedWork W1585256759 @default.
• W4282922251 hasRelatedWork W1940682904 @default.
• W4282922251 hasRelatedWork W2113265247 @default.
• W4282922251 hasRelatedWork W2559207392 @default.
• W4282922251 hasRelatedWork W2602761843 @default.
• W4282922251 hasRelatedWork W2766006694 @default.
• W4282922251 hasRelatedWork W2771056243 @default.
• W4282922251 hasRelatedWork W2914484697 @default.
• W4282922251 hasRelatedWork W4205550511 @default.
• W4282922251 hasRelatedWork W4225904185 @default.
• W4282922251 hasVolume "82" @default.
• W4282922251 isParatext "false" @default.
• W4282922251 isRetracted "false" @default.
• W4282922251 workType "article" @default.